Home Transmembrane Transporters NKCC inhibitor Furosemide (NSC 269420)

Furosemide (NSC 269420)

Catalog No.S1603

For research use only.

Furosemide (NSC 269420) is a potent NKCC2 (Na-K-2Cl symporter) inhibitor, used in the treatment of congestive heart failure and edema.

Furosemide (NSC 269420) Chemical Structure

CAS No. 54-31-9

Selleck's Furosemide (NSC 269420) has been cited by 4 Publications

Purity & Quality Control

Choose Selective NKCC Inhibitors

Related Compound Libraries

Biological Activity

Description Furosemide (NSC 269420) is a potent NKCC2 (Na-K-2Cl symporter) inhibitor, used in the treatment of congestive heart failure and edema.
Targets
NKCC2 [4]
In vitro

Furosemide reversibly alters the responses to tones and clicks of the chinchilla basilar membrane in hair cells, causing response-magnitude reductions that are largest (up to 61 dB, averaging 25-30 dB) at low stimulus intensities at the characteristic frequency (CF) and small or nonexistent at high intensities and at frequencies far removed from CF. Furosemide also induces response-phase lags that are largest at low stimulus intensities (averaging 77 degrees) and are confined to frequencies close to CF. [1] Furosemide concentration- and time-dependently increases the formation of nitric oxide andprostacyclin. Furosemide leads to an enhanced release of kinins into the supernatant of the cells. [2] Furosemide reversibly suppresses low Ca2+-induced epileptiform activity in hippocampus proper and blocks or significantly reduces different types of epileptiform discharges in the low Mg2+ model and the 4-aminopyridine model. [3] Furosemide significantly inhibits cell growth in MKN45 cells, but not in MKN28 cells. Furosemide diminishes cell growth by delaying the G(1)-S phase progression in poorly differentiated gastric adenocarcinoma cells, which show high expression and activity of NKCC, but not in moderately differentiated gastric adenocarcinoma cells with low expression and NKCC activity. [4]
In vivo Furosemide (0.25 to 2 mg/kg), administered 4 hours before exercise, reduces right atrial pressure (RAP) and pulmonary arterial pressure (PAP) during exercise in dose-dependent manner in horse. [5]

Protocol (from reference)

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight 330.74
Formula

C12H11ClN2O5S
CAS No. 54-31-9
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT05305495 Not yet recruiting Drug: Empagliflozin 25 MG Acute Heart Failure|Chronic Kidney Diseases McGill University Health Centre/Research Institute of the McGill University Health Centre July 2022 Phase 4
NCT05392764 Not yet recruiting Drug: Empagliflozin 10 MG|Drug: Placebo Acute Heart Failure Juntendo University|Boehringer Ingelheim June 10 2022 Phase 3
NCT04331132 Not yet recruiting Drug: Tolvaptan 15 MG Acute Heart Failure Gia Dinh People Hospital|Otsuka Pharmaceutical Vietnam December 1 2021 Not Applicable
NCT04972617 Not yet recruiting Diagnostic Test: albumin function analysis (ABIC) Acute Renal Failure|Critical Illness University of Rostock September 2021 --
NCT05098366 Recruiting Drug: Furosemide|Drug: Normal saline Ovarian Torsion Connecticut Children''s Medical Center May 29 2021 Early Phase 1

(data from https://clinicaltrials.gov, updated on 2022-08-01)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Furosemide (NSC 269420) | Furosemide (NSC 269420) supplier | purchase Furosemide (NSC 269420) | Furosemide (NSC 269420) cost | Furosemide (NSC 269420) manufacturer | order Furosemide (NSC 269420) | Furosemide (NSC 269420) distributor